Monitoring acute and longer-term effects of cannabis on psychomotor performance in daily life in medical cannabis patients

监测大麻对医用大麻患者日常生活中精神运动表现的急性和长期影响

• 批准号: 10657179
• 负责人: Tammy Chung
• 金额: $ 76.26万
• 依托单位: RUTGERS BIOMEDICAL AND HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-15 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10657179
• 关键词: Accelerometer; Acute; Adverse effects; Age; Alcohols; Anxiety; Automobile Driving; Awareness; Cannabis; Cellular Phone; Cognitive; Collaborations; Data; Data Collection; Development; Digit structure; Drug usage; Ecological momentary assessment; Exclusion; Female; Frequencies; Goals; Grain; Impairment; Individual; Intervention; Intoxication; Life; Link; Measures; Mediating; Mediation; Medical; Medical Marijuana; Methods; Modeling; Monitor; National Institute of Drug Abuse; Outcome; Pain; Participant; Patient Self-Report; Patients; Performance at work; Persons; Pharmaceutical Preparations; Psychomotor Performance; Reaction; Reaction Time; Reporting; Risk; Risk Reduction; Speed; Substance Use Disorder; Symptoms; Telephone; Testing; Therapeutic; Therapeutic Effect; Therapeutic Uses; Time; Visit; alcohol and other drug; anxiety symptoms; chronic pain; cognitive function; computerized; design; driving skills; follow-up; gender difference; improved; interest; mHealth; marijuana use; marijuana use disorder; novel; pain symptom; recruit; response; saliva sample; salivary assay; self-reported anxiety; sensor; side effect

ABSTRACT Although therapeutic use of cannabis is increasing, findings are mixed regarding therapeutic effects of cannabis for certain conditions, such as anxiety. Further, acute cannabis effects could adversely impact psychomotor performance (e.g., slowed reaction time), with subsequent negative effects on daily activities (e.g., work performance, driving skills). Low burden methods to monitor acute cannabis effects through sensors in personal smartphones could ultimately help reduce cannabis's acute negative effects on psychomotor performance by helping to raise a person's awareness of cannabis-related impairment. Toward this goal, this R01 will collaborate with individuals who use medical cannabis (MC) in monitoring, with their smartphone, acute therapeutic and adverse effects of cannabis use. Individuals who use MC commonly report cannabis use to relieve chronic pain and/or anxiety, the two conditions of interest for this R01. Smartphone will be used to conduct symptom monitoring of acute cannabis effects on chronic pain and anxiety using Ecological Momentary Assessment (EMA). Phone sensor data will be used to examine acute cannabis effects on psychomotor performance. These fine-grained smartphone "micro" data (e.g., momentary-level) will be combined with longer-term follow-up over 1-year, to examine the impact of cannabis use at a more "macro" level (e.g., over months), because cannabis effects (e.g., on anxiety) at "micro" and "macro" time scales may differ. This R01 will recruit individuals who report therapeutic use of cannabis, with chronic pain and/or anxiety as the primary reasons for MC use (N=400, age >18; 50% female). Participants complete lab assessments at baseline, 3-, 6-, and 12-months in a repeated measures design. Saliva sample for THC and CBD level will be done at baseline, 3-, 6-, and 12-months. Each assessment (baseline, 3-, 6-, 12-months) is followed by 14-day daily EMA and phone sensor data collection. Daily EMA (3x/day) and self-initiated EMA of cannabis use (medical, non-medical) will be used. Phone sensor data include, for example, keyboard use (not message content), and accelerometer (e.g., to detect activity level). Study aim 1 will examine links between acute cannabis use and effects (EMA report), psychomotor performance (phone sensor data), and self-reported daily cognitive functioning (e.g., react slowly to things). Study aim 2 will test links, over 1-year, of longer-term effects of cannabis use, computerized measures of psychomotor performance, and self-report of cannabis-related consequences. For each aim, gender differences in cannabis's short and longer term effects will be explored. The combination of fine-grained subjective (EMA) and objective (phone sensor) data, collected at micro (EMA) and macro time scales over 1-year, will help resolve mixed findings on possible cannabis-related therapeutic benefit, acute risks, and longer-term outcomes (e.g., on psychomotor performance). In line with NIDA priorities, this R01's novel combination of symptom monitoring methods (EMA, phone sensor data), and "micro" and "macro" data, will guide development of mHealth interventions that reduce risk for cannabis-related harm.

抽象的 尽管大麻的治疗用途正在增加，但关于大麻的治疗效果的研究结果却好坏参半。 大麻用于某些情况，例如焦虑。此外，急性大麻效应可能会产生不利影响 精神运动表现（例如反应时间减慢），随后对日常活动产生负面影响 （例如，工作表现、驾驶技能）。通过低负担方法监测大麻的急性影响 个人智能手机中的传感器最终可能有助于减少大麻对人的严重负面影响 通过帮助提高人们对大麻相关障碍的认识来提高精神运动表现。走向 为了实现这一目标，R01 将与使用医用大麻 (MC) 的个人合作进行监测， 智能手机、大麻使用的急性治疗和副作用。使用 MC 的个人普遍报告 使用大麻来缓解慢性疼痛和/或焦虑，这是 R01 感兴趣的两种情况。智能手机将 使用生态学方法对大麻对慢性疼痛和焦虑的急性影响进行症状监测 瞬时评估（EMA）。手机传感器数据将用于检查大麻对人的急性影响 精神运动表现。这些细粒度的智能手机“微观”数据（例如瞬时级别）将被 结合1年多的长期随访，以更“宏观”的角度审视大麻使用的影响 水平（例如，几个月），因为大麻在“微观”和“宏观”时间尺度上的影响（例如，对焦虑）可能 不同。该 R01 将招募报告使用大麻治疗慢性疼痛和/或焦虑的个人 作为使用 MC 的主要原因（N=400，年龄 >18；50% 女性）。参与者完成实验室评估 重复测量设计中的基线、3 个月、6 个月和 12 个月。 THC 和 CBD 水平的唾液样本将是 在基线、3 个月、6 个月和 12 个月时完成。每次评估（基线、3、6、12 个月）后均进行 14 天的评估 每日 EMA 和电话传感器数据收集。每日 EMA（3 次/天）和自行发起的大麻使用 EMA （医疗、非医疗）将被使用。手机传感器数据包括例如键盘使用情况（不是消息 内容）和加速度计（例如，检测活动水平）。研究目标 1 将检验急性发作之间的联系 大麻的使用和影响（EMA 报告）、精神运动表现（手机传感器数据）以及每日自我报告 认知功能（例如，对事物反应缓慢）。研究目标 2 将测试一年多的长期影响的联系 大麻使用情况、精神运动表现的计算机化测量以及大麻相关的自我报告 结果。对于每个目标，都将探讨大麻短期和长期影响的性别差异。 在微观 (EMA) 收集的细粒度主观 (EMA) 和客观（手机传感器）数据的组合 和一年以上的宏观时间尺度，将有助于解决可能与大麻相关的治疗的混合结果 益处、急性风险和长期结果（例如，精神运动表现）。根据 NIDA 的优先事项， 这款 R01 新颖地将症状监测方法（EMA、手机传感器数据）与“微”和 “宏观”数据将指导移动医疗干预措施的制定，以降低大麻相关危害的风险。